➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Boehringer Ingelheim
Harvard Business School
McKinsey
Medtronic

Last Updated: July 3, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR IMLYGIC

» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for IMLYGIC

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00289016 A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma Completed Symbion Research International Phase 2 2005-12-01 The primary objective of the study was to assess the clinical efficacy of talimogene laherparepvec in terms of tumor response rates.
NCT00289016 A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma Completed BioVex Limited Phase 2 2005-12-01 The primary objective of the study was to assess the clinical efficacy of talimogene laherparepvec in terms of tumor response rates.
NCT01161498 Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer Terminated Amgen Phase 3 2011-02-01 This study is being conducted to learn about the safety and risks of using talimogene laherparepvec to treat patients with head and neck cancer and to see if talimogene laherparepvec and chemoradiation together can destroy the tumours versus the use of chemoradiation alone. This study may provide information on the usefulness of talimogene laherparepvec combined with chemoradiation as a future treatment for head and neck cancer.
NCT01161498 Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer Terminated BioVex Limited Phase 3 2011-02-01 This study is being conducted to learn about the safety and risks of using talimogene laherparepvec to treat patients with head and neck cancer and to see if talimogene laherparepvec and chemoradiation together can destroy the tumours versus the use of chemoradiation alone. This study may provide information on the usefulness of talimogene laherparepvec combined with chemoradiation as a future treatment for head and neck cancer.
NCT03088176 Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma Recruiting Amgen Phase 1 2017-06-25 The purpose of the study is to determine safety and tolerability of the combination of talimogene laherparepvec in combination with dabrafenib and trametinib in BRAF mutated advanced melanoma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for IMLYGIC

Condition Name

Condition Name for IMLYGIC
Intervention Trials
Melanoma 2
Squamous Cell Carcinoma 2
Stage IIIC Rectal Cancer AJCC v7 1
Prognostic Stage III Breast Cancer AJCC v8 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for IMLYGIC
Intervention Trials
Melanoma 3
Carcinoma 2
Breast Neoplasms 2
Carcinoma, Squamous Cell 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for IMLYGIC

Trials by Country

Trials by Country for IMLYGIC
Location Trials
United States 16
United Kingdom 2
Spain 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for IMLYGIC
Location Trials
Texas 2
California 2
New York 1
New Jersey 1
Minnesota 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for IMLYGIC

Clinical Trial Phase

Clinical Trial Phase for IMLYGIC
Clinical Trial Phase Trials
Phase 3 1
Phase 2 3
Phase 1/Phase 2 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for IMLYGIC
Clinical Trial Phase Trials
Recruiting 4
Not yet recruiting 3
Terminated 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for IMLYGIC

Sponsor Name

Sponsor Name for IMLYGIC
Sponsor Trials
Amgen 6
BioVex Limited 2
CareFusion 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for IMLYGIC
Sponsor Trials
Industry 11
Other 7
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Medtronic
Harvard Business School
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.